Lisa R. Tannock, MD

Chief, Division of Endocrinology and Molecular Medicine

Clinical interests

  • Diabetes
  • General Endocrinology
  • Lipids
  • Metabolic Disease

Lisa R. Tannock, MD

Chief, Division of Endocrinology and Molecular Medicine

Biography

My name is Lisa Tannock; I received my medical degree from the University of Toronto, Ontario, Canada. I then completed a fellowship at the University of Washington Medical Center, Seattle. I joined the University of Kentucky in 2004, and became division chief in 2007, and associate chair of internal medicine for administration in 2014.

I am board certified by the American Board of Internal Medicine in Endocrinology and Metabolism. I have been the associate editor of the peer-reviewed journal, Atherosclerosis, since 2008. I am associate director of the Barnstable Brown Diabetes and Obesity Center and an incoming editor in chief for the Endocrine Self Assessment Program.

My research interests include studying how diabetes and obesity complications develop. My clinical interests include diabetes and insulin resistance, cholesterol disorders and transgender medicine.

Faculty rank

Professor of Medicine

Education

Degree
University of Toronto, Ontario, Canada

Residency
University of Toronto Hospitals, Ontario, Canada

Fellowship
University of Washington Medical Center, Seattle

Certifications or Special training
American Board of Internal Medicine, Endocrinology and Metabolism 

Endocrinology

Medicine Specialties

Kentucky Clinic
Second Floor, Wing C
740 S. Limestone
Lexington KY 40536-0284

Call 859-323-2232
Fax 859-257-2634

Amenities
Dining, Internet/Wi-Fi, Information desk, Pharmacy services, Wheelchairs

Kentucky Clinic Map (PDF, 616 KB) »
Directions to Kentucky Clinic Parking »


UK HealthCare accepts many forms of insurance. See list of insurers »

 
  1. Grandoch M, Kohlmorgen C, Melchior-Becker A, Feldmann K, Homann S, Müller J, Kiene LS, Zeng-Brouwers J, Schmitz F, Nagy N, Polzin A, Gowert NS, Elvers M, Skroblin P, Yin X, Mayr M, Schaefer L, Tannock LR, Fischer JW. Loss of Biglycan Enhances Thrombin Generation in Apolipoprotein E-Deficient Mice: Implications for Inflammation and Atherosclerosis. Arterioscler Thromb Vasc Biol. 2016 May;36(5):e41-50.
    View in: PubMed
  2. Palladino CE, Eberly ME, Emmons JT, Tannock LR. Management of U-500 insulin users during inpatient admissions within a Veterans Affairs Medical Center. Diabetes Res Clin Pract. 2016 Apr;114:32-6.
    View in: PubMed
  3. Thompson JC, Jayne C, Thompson J, Wilson PG, Yoder MH, Webb N, Tannock LR. A brief elevation of serum amyloid A is sufficient to increase atherosclerosis. J Lipid Res. 2015 Feb;56(2):286-93.
    View in: PubMed
  4. Tannock LR. Vascular proteoglycans and atherosclerosis: not over yet. Atherosclerosis. 2014 Dec;237(2):435-6.
    View in: PubMed
  5. Tang T, Thompson JC, Wilson PG, Yoder MH, Müeller J, Fischer JW, Williams KJ, Tannock LR. Biglycan deficiency: increased aortic aneurysm formation and lack of atheroprotection. J Mol Cell Cardiol. 2014 Oct;75:174-80.
    View in: PubMed
  6. Hatch NW, Srodulski SJ, Chan HW, Zhang X, Tannock LR, King VL. Endogenous androgen deficiency enhances diet-induced hypercholesterolemia and atherosclerosis in low-density lipoprotein receptor-deficient mice. Gend Med. 2012 Oct; 9(5):319-28. PMID: 22981166.
    View in: PubMed
  7. Tang T, Thompson JC, Wilson PG, Nelson C, Williams KJ, Tannock LR. Decreased Body Fat, Elevated Plasma Transforming Growth Factor-ß Levels, and Impaired BMP4-Like Signaling in Biglycan-Deficient Mice. Connect Tissue Res. 2013; 54(1):5-13. PMID: 22834985.
    View in: PubMed
  8. Dailey AM, Gibert JA, Tannock LR. Durability of glycemic control using U-500 insulin. Diabetes Res Clin Pract. 2012 Mar; 95(3):340-4. PMID: 22088791.
    View in: PubMed
  9. Tannock LR. Ursolic acid effect on atherosclerosis: apples and apples, or apples and oranges? Atherosclerosis. 2011 Dec; 219(2):397-8. PMID: 21993411.
    View in: PubMed
  10. King VL, Thompson J, Tannock LR. Serum amyloid A in atherosclerosis. Curr Opin Lipidol. 2011 Aug; 22(4):302-7. PMID: 21734573.
    View in: PubMed
  11. Thompson J, Wilson P, Brandewie K, Taneja D, Schaefer L, Mitchell B, Tannock LR. Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy. Am J Pathol. 2011 Sep; 179(3):1179-87. PMID: 21723246.
    View in: PubMed
  12. Dailey AM, Tannock LR. Extreme insulin resistance: indications and approaches to the use of U-500 insulin in type 2 diabetes mellitus. Curr Diab Rep. 2011 Apr; 11(2):77-82. PMID: 21161448.
    View in: PubMed
  13. Yang SN, Burch ML, Tannock LR, Evanko S, Osman N, Little PJ. Transforming growth factor-ß regulation of proteoglycan synthesis in vascular smooth muscle: contribution to lipid binding and accelerated atherosclerosis in diabetes. J Diabetes. 2010 Dec; 2(4):233-42. PMID: 20923499.
    View in: PubMed
  14. Tannock LR, King VL. Animal models of atherosclerosis: more than mice. Atherosclerosis. 2010 Sep; 212(1):32-3. PMID: 20638066.
    View in: PubMed
  15. Dailey AM, Williams S, Taneja D, Tannock LR. Clinical efficacy and patient satisfaction with U-500 insulin use. Diabetes Res Clin Pract. 2010 Jun; 88(3):259-64. PMID: 20226557.
    View in: PubMed
  16. Taneja D, Thompson J, Wilson P, Brandewie K, Schaefer L, Mitchell B, Tannock LR. Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice. J Lipid Res. 2010 Jun; 51(6):1464-70. PMID: 20110440.
    View in: PubMed
  17. Brown A, Desai M, Taneja D, Tannock LR. Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management. Postgrad Med. 2010 Jan; 122(1):163-71. PMID: 20107300.
    View in: PubMed
  18. Ballinger ML, Osman N, Hashimura K, de Haan JB, Jandeleit-Dahm K, Allen T, Tannock LR, Rutledge JC, Little PJ. Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo. J Cell Mol Med. 2010 Jun; 14(6B):1408-18. PMID: 19754668.
    View in: PubMed
  19. Qiao M, Zhao Q, Lee CF, Tannock LR, Smart EJ, LeBaron RG, Phelix CF, Rangel Y, Asmis R. Thiol oxidative stress induced by metabolic disorders amplifies macrophage chemotactic responses and accelerates atherogenesis and kidney injury in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2009 Nov; 29(11):1779-86. PMID: 19592463.
    View in: PubMed
  20. King VL, Hatch NW, Chan HW, de Beer MC, de Beer FC, Tannock LR. A murine model of obesity with accelerated atherosclerosis. Obesity (Silver Spring). 2010 Jan; 18(1):35-41. PMID: 19498343.
    View in: PubMed
  21. Jahangiri A, de Beer MC, Noffsinger V, Tannock LR, Ramaiah C, Webb NR, van der Westhuyzen DR, de Beer FC. HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol. 2009 Feb; 29(2):261-7. PMID: 19008529.
    View in: PubMed
  22. Wilson PG, Thompson JC, Webb NR, de Beer FC, King VL, Tannock LR. Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner. Am J Pathol. 2008 Dec; 173(6):1902-10. PMID: 18974302.
    View in: PubMed
  23. Reynolds LR, Tannock LR. Management of new-onset diabetes mellitus after transplantation. Postgrad Med. 2008 Jul; 120(2):60-6. PMID: 18654070.
    View in: PubMed
  24. Tannock LR, King VL. Proteoglycan mediated lipoprotein retention: a mechanism of diabetic atherosclerosis. Rev Endocr Metab Disord. 2008 Dec; 9(4):289-300. PMID: 18584330.
    View in: PubMed
  25. Little PJ, Drennon KD, Tannock LR. Glucosamine inhibits the synthesis of glycosaminoglycan chains on vascular smooth muscle cell proteoglycans by depletion of ATP. Arch Physiol Biochem. 2008 Apr; 114(2):120-6. PMID: 18484279.
    View in: PubMed
  26. Tannock LR, Reynolds LR. Management of dyslipidemia in patients after solid organ transplantation. Postgrad Med. 2008 Apr; 120(1):43-9. PMID: 18467808.
    View in: PubMed
  27. Tannock LR. Advances in the management of hyperlipidemia-induced atherosclerosis. Expert Rev Cardiovasc Ther. 2008 Mar; 6(3):369-83. PMID: 18327996.
    View in: PubMed
  28. Cai L, Ji A, de Beer FC, Tannock LR, van der Westhuyzen DR. SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J Clin Invest. 2008 Jan; 118(1):364-75. PMID: 18064300.
    View in: PubMed
  29. Huang F, Thompson JC, Wilson PG, Aung HH, Rutledge JC, Tannock LR. Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. J Lipid Res. 2008 Mar; 49(3):521-30. PMID: 18033753.
    View in: PubMed
  30. Reynolds LR, Kingsley FJ, Karounos DG, Tannock LR. Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes. Diabetes Res Clin Pract. 2007 Aug; 77(2):180-7. PMID: 17239474.
    View in: PubMed
  31. Wilson P, Drennon K, Tannock LR. Regulation of vascular proteoglycan synthesis by metabolic factors associated with diabetes. J Investig Med. 2007 Jan; 55(1):18-25. PMID: 17441408.
    View in: PubMed
  32. Tannock LR, Kirk EA, King VL, LeBoeuf R, Wight TN, Chait A. Glucosamine supplementation accelerates early but not late atherosclerosis in LDL receptor-deficient mice. J Nutr. 2006 Nov; 136(11):2856-61. PMID: 17056813.
    View in: PubMed
  33. Tannock LR. Proteoglycans can mediate renal lipoprotein retention. Diabetologia. 2006 May; 49(5):1115-6. PMID: 16532326.
    View in: PubMed
  34. Tannock LR, O'Brien KD, Knopp RH, Retzlaff B, Fish B, Wener MH, Kahn SE, Chait A. Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects. Circulation. 2005 Jun 14; 111(23):3058-62. PMID: 15939816.
    View in: PubMed
  35. Renard CB, Kramer F, Johansson F, Lamharzi N, Tannock LR, von Herrath MG, Chait A, Bornfeldt KE. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest. 2004 Sep; 114(5):659-68. PMID: 15343384.
    View in: PubMed
  36. Tannock LR, Chait A. Lipoprotein-matrix interactions in macrovascular disease in diabetes. Front Biosci. 2004 May 1; 9:1728-42. PMID: 14977582.
    View in: PubMed
  37. Tannock LR, Little PJ, Tsoi C, Barrett PH, Wight TN, Chait A. Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans. Diabetologia. 2004 May; 47(5):837-43. PMID: 15071727.
    View in: PubMed
  38. Meyers CD, Tannock LR, Wight TN, Chait A. Statin-exposed vascular smooth muscle cells secrete proteoglycans with decreased binding affinity for LDL. J Lipid Res. 2003 Nov; 44(11):2152-60. PMID: 12923222.
    View in: PubMed
  39. Herbst KL, Tannock LR, Deeb SS, Purnell JQ, Brunzell JD, Chait A. Köbberling type of familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care. 2003 Jun; 26(6):1819-24. PMID: 12766116.
    View in: PubMed
  40. Tannock LR, Little PJ, Wight TN, Chait A. Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. J Lipid Res. 2002 Jan; 43(1):149-57. PMID: 11792734.
    View in: PubMed
  41. Tannock LR, Olin KL, Barrett PH, Wight TN, Chait A. Triglyceride-rich lipoproteins from subjects with type 2 diabetes do not demonstrate increased binding to biglycan, a vascular proteoglycan. J Clin Endocrinol Metab. 2002 Jan; 87(1):35-40. PMID: 11788619.
    View in: PubMed
  42. Little PJ, Tannock L, Olin KL, Chait A, Wight TN. Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs. Arterioscler Thromb Vasc Biol. 2002 Jan; 22(1):55-60. PMID: 11788461.
    View in: PubMed
  43. Douville EM, Afar DE, Howell BW, Letwin K, Tannock L, Ben-David Y, Pawson T, Bell JC. Multiple cDNAs encoding the esk kinase predict transmembrane and intracellular enzyme isoforms. Mol Cell Biol. 1992 Jun; 12(6):2681-9. PMID: 1375325.
    View in: PubMed
  44. Ben-David Y, Letwin K, Tannock L, Bernstein A, Pawson T. A mammalian protein kinase with potential for serine/threonine and tyrosine phosphorylation is related to cell cycle regulators. EMBO J. 1991 Feb; 10(2):317-25. PMID: 1825055.
    View in: PubMed